New drug combo offers hope for Hard-to-Treat breast cancer
NCT ID NCT07037199
First seen Jan 04, 2026 · Last updated Jun 16, 2026 · Updated 26 times
Summary
This study tests a two-step treatment plan for people with advanced breast cancer that is hormone-receptor-positive and HER2-low or ultra-low. First, participants receive a targeted drug called trastuzumab rezetecan for several months. Then, they switch to a combination of a CDK4/6 inhibitor and hormone therapy to keep the cancer under control. The goal is to see how long the cancer stays stable and to monitor side effects. About 45 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen Memorial Hospital
RECRUITINGGuangzhou, Guangdong, 510120, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.